FEI CO
Healthcare · Laboratory Analytical Instruments · OR · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY15 | FY14 | FY13 | FY12 | FY11 | FY10 | |
|---|---|---|---|---|---|---|
| Revenue | $930.1M | $956.3M | $927.5M | $891.7M | $826.4M | $634.2M |
| Operating income | $151.4M | $129.4M | $156.2M | $148.1M | $127.1M | $55.5M |
| Net income | $124.0M | $105.1M | $126.7M | $114.9M | $103.6M | $53.5M |
| Total assets | $1.35B | $1.42B | $1.43B | $1.23B | $1.09B | $984.4M |
| Total liabilities | — | — | — | — | — | — |
| Equity | $990.1M | $1.04B | $1.08B | $839.9M | $696.8M | $633.2M |
| EPS (diluted) | $2.96 | $2.47 | $3.01 | $2.80 | $2.51 | $1.34 |
| Shares out. | 41.8M | 42.2M | 38.5M | 37.9M | 38.6M | 38.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2015- Operating margin
- 16.3%
- Net margin
- 13.3%
- Return on equity
- 12.5%
- Return on assets
- 9.2%
- Return on capital (ROCE)
- 14.1%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $23.68
- Revenue growth (YoY)
- −2.7%
- Net income growth (YoY)
- 18.0%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2015- Accruals / assets
- −6.0%clean
- Piotroski F-Score
- 7/8strong
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 warning● 3 good- Revenue declined year-over-year
- Operating margin is positive
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 2Recruitingreadout ~2025-06-30TIPS Plus Cadonilimab in Advanced HCC with Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II Study
- Phase 2Not Yet Recruitingreadout ~2026-03-26A Practical Clinical Study Comparing the Fixed-cycle Regimen Containing Orelabrutinib With BTKi Monotherapy
- Phase 2Recruitingreadout ~2026-05-04Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial
- Phase 2Recruitingreadout ~2026-05-31TIPS Plus Half-dose Donafenib in AHCC with PVTT-associated Portal Hypertension
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Wills Richard HDirector | Sep 19, 2016 | U | 11,930 | — |
| Nachtsheim Jami KDirector | Sep 19, 2016 | U | 7,430 | — |
| Kania Don ROfficer — See Remarks | Sep 19, 2016 | U | 48,486 | — |
| Richardson James TDirector | Sep 19, 2016 | U | 13,555 | — |
| Kelly Thomas FDirector | Sep 19, 2016 | U | 16,930 | — |
| Lobbezoo Jan CDirector | Sep 19, 2016 | U | 16,930 | — |
| Thies Bradley JOfficer — See Remarks | Sep 19, 2016 | U | 15,972 | — |
| Bahrami HomaDirector | Sep 19, 2016 | U | 7,430 | — |
| Huijser ArieDirector | Sep 19, 2016 | U | 2,930 | — |
| Trunzo Anthony LOfficer — Executive VP, CFO | Aug 10, 2016 | Option exercise | 21,030 | $79.94 |
| Thies Bradley JOfficer — Sr. VP-General Counsel | May 23, 2016 | Option exercise | 1,172 | $89.99 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Amended charter or bylaws · Other material eventSep 23, 2016
- Shareholder voteAug 30, 2016
- Results of operationsAug 4, 2016
- Other material eventJun 27, 2016
- Other material eventJun 9, 2016
- Entered a material agreementJun 2, 2016
- Other material eventMay 27, 2016
- Director / officer changeMay 17, 2016
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.